Skip to main content
Equibles

Pablo Legorreta

CEO

Royalty Pharma plc (RPRX)

Equibles does not estimate personal net worth.

Get an email with a short summary when Royalty Pharma plc publishes a filing, an earnings call transcript or a press release.

Get RPRX alerts

About Pablo Legorreta

Pablo Legorreta is recorded as CEO at Royalty Pharma plc (RPRX). The newest filing on record that lists Pablo Legorreta as CEO at Royalty Pharma plc (RPRX) is dated April 10, 2026. The proxy statement of Royalty Pharma plc reports total compensation of $937,500 for Pablo Legorreta in fiscal 2025, including a base salary of $937,500. Pablo Legorreta has spoken on 23 earnings calls and 1 other investor event across 1 company, most recently for Royalty Pharma plc on September 14, 2026. Royalty Pharma plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Royalty Pharma plc includes Vlad Coric (CEO and Board Member), Christopher Hite (Chairman), David Hodgson (Chairman) and 7 others.

Pablo Legorreta on recent calls

“First of all, thank you for the invitation to participate in your conference and for the relationship with you and Morgan Stanley, which has been key to our growth over decades.”
CEO, Royalty Pharma at the Morgan Stanley 24th Annual Global Healthcare Conference ·
“I am pleased to report another quarter of strong financial performance and disciplined execution.”
CEO, Royalty Pharma Q2 2026 Financial Results Call ·
“I am happy to report a strong start to 2026 as we execute towards our goal to be the premier capital allocator in life sciences with consistent compounding growth.”
CEO, Royalty Pharma plc Q1 FY2026 Earnings Call ·
“2025 was truly a landmark year for Royalty Pharma as we executed successfully towards our goal to be the premier capital allocator in life sciences with consistent compounding growth.”
CEO, Royalty Pharma plc Q4 FY2025 Earnings Call ·
“I am delighted to report another successful quarter of execution on our goal to be the premier capital allocator in life sciences with consistent compounding growth.”
CEO, Royalty Pharma plc Q3 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Royalty Pharma plc

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Royalty Pharma plc (RPRX) $937,500 $937,500

Recent activity

Show 12 earlier activities